TEVA Pharmaceuticals and
Allergan overnight confirmed that
Teva will buy Allergan’s generic
drug business (PD yesterday), with
Teva also formally withdrawing its
rival offer for Mylan.
After the acquisition Teva will
have a commercial presence in 100
markets, with the company saying
it will “help eliminate inefficiencies
and duplications in the global
generics space”.
Teva will acquire Allergan’s Actavis
operations globally, the firm’s
generics R&D unit, the international
OTC commercial unit and its global
manufacturing operations.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jul 15
THOUGH women make up 60% of pharmacy graduates and pharmacists, they hold only 34% of leadership and ownership roles, according to Andria Aird, a community pharmacist, pharmacy owner, and Board Director of Blooms The Chemist.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.